US 12,478,676 B2
Method of imaging
Andrew John Healey, Moss (NO); Per Christian Sontum, Oslo (NO); and Svein Kvale, As (NO)
Assigned to Exact Therapeutics AS, Oslo (NO)
Filed by EXACT THERAPEUTICS AS, Oslo (NO)
Filed on Mar. 21, 2023, as Appl. No. 18/187,248.
Application 18/187,248 is a division of application No. 15/024,265, abandoned, previously published as PCT/NO2014/050177, filed on Sep. 26, 2014.
Claims priority of application No. 20131293 (NO), filed on Sep. 27, 2013.
Prior Publication US 2023/0218759 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/337 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 9/16 (2006.01); A61K 9/19 (2006.01); A61K 31/454 (2006.01); A61K 31/475 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 41/00 (2020.01); A61K 49/00 (2006.01); A61K 49/22 (2006.01); A61L 24/00 (2006.01); A61P 7/04 (2006.01)
CPC A61K 41/0047 (2013.01) [A61K 9/0009 (2013.01); A61K 9/1075 (2013.01); A61K 9/16 (2013.01); A61K 9/19 (2013.01); A61K 31/337 (2013.01); A61K 31/454 (2013.01); A61K 31/475 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 41/0028 (2013.01); A61K 49/0078 (2013.01); A61K 49/223 (2013.01); A61L 24/001 (2013.01); A61L 24/0015 (2013.01); A61P 7/04 (2018.01); A61L 2300/418 (2013.01); A61L 2300/45 (2013.01); A61L 2300/62 (2013.01); A61L 2430/36 (2013.01)] 9 Claims
 
1. A method of high frequency sound wave imaging control of agent delivery to a subject, the method comprising:
administering a two-component, bi-phasic formulation and a separate therapeutic agent to the subject, wherein the therapeutic agent is selected from the group consisting of genes, chemotherapeutics and immunotherapeutics;
imaging a plurality of gaseous components of the bi-phasic formulation to identify a region of interest within said subject;
activating a phase shift of a vaporous component of the bi-phasic formulation by a first high frequency sound wave application of the region of interest, such that individual gaseous components are enlarged by the vaporous component to give enlarged individual gaseous components localised at the region of interest;
applying a second high frequency sound wave to the region of interest to oscillate the enlarged gaseous components; and
analysing the acoustic signature produced by the enlarged gaseous components to quantify the amount of therapeutic agent delivered,
wherein the therapeutic agent is delivered separately from the bi-phasic formulation, and wherein the first high frequency is different from the second high frequency and wherein the second high frequency sound wave comprises a frequency in the range of 0.05 to 1 MHz.